4-(4-氟苯甲酰基)-1-(2-羟乙基)哌啶 | 106088-85-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(4-氟苯甲酰基)-1-(2-羟乙基)哌啶
• 英文名称: 4-(4-fluorobenzoyl)-1-(2-hydroxyethyl)piperidine
• 英文别名: 1-(2-hydroxyethyl)-4-(4-fluorobenzoyl)piperidine；2-[4-(p-fluorobenzoyl)piperidino]ethanol；(4-fluoro-phenyl)-[1-(2-hydroxy-ethyl)-piperidin-4-yl]-methanone；4-(4-fluorobenzoyl)-1(2-hydroxyethyl)piperidine；(4-fluorophenyl)-[1-(2-hydroxyethyl)piperidin-4-yl]methanone
• CAS: 106088-85-1
• 化学式: C₁₄H₁₈FNO₂
• 分子量: 251.301
• InChiKey: QRLFOJWBXIEVJA-UHFFFAOYSA-N

物化性质

• 沸点：
  394.1±37.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-氟苯甲酰基)-1-(2-羟乙基)哌啶 在 四氯化碳 、 三苯基膦 作用下， 以 吡啶 为溶剂， 反应 1.0h， 以77%的产率得到1-(2-chloroethyl)-4-(4-fluorobenzoyl)piperidine
  参考文献：
  名称：

  Substituted 3-amino and/or 3-aminomethyl-3,4-dihydro-2 H -1-benzopyrans: synthesis and biological activity

  摘要：

  A series of new 3-amino, 3-aminomethyl-5-alkoxy-3,4-dihydro-2H-1-benzopyran and 5-alkoxy-3',4'-dihydrospiro[piperazine-2,3'(2'H)-benzopyran] derivatives was prepared and evaluated for affinity at 5-HT1A, 5-HT2A and D-2 receptors. Two of the compounds (1f and 2b) can be considered as potent and selective 5-HT2A ligands. One compound (1g) demonstrated high affinity for 5-HT1A and D-2 receptor binding sites and one compound (1d) proved to be a mixed 5-HT1A/5-HT2A ligand. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00311-9
• 作为产物：
  描述：

  4-(4-氟苯甲酰基)哌啶 、 2-溴乙醇 在 氩 、 三乙胺 、 disodium;carbonate 、 乙酸乙酯 作用下， 以 三乙胺 为溶剂， 反应 1.0h， 以to obtain 1.96 g (78.0%) of the title compound in the form of light yellow solid的产率得到4-(4-氟苯甲酰基)-1-(2-羟乙基)哌啶
  参考文献：
  名称：

  Substituted cyclic amine compound, production process thereof and

  摘要：

  以下是一种由下列通式（1）表示的取代环氨基化合物：##STR1## 其中，R.sup.1至R.sup.5中的每一个代表氢原子、卤素原子、低烷基、低烷氧基或类似物，A代表羰基或磺酰基，B代表亚甲基或氮原子，D代表亚甲基、氮原子或.dbd.N(.fwdarw.O)--，n为2至3的整数；以及其合成方法。该创新化合物可用于预防和治疗循环器官相关疾病，如高血压、缺血性心脏病、脑血管疾病、外周循环疾病等。

  公开号：

  US05728835A1

文献信息

• Heterocyclic compound having serotonine 2-receptor antagonistic activity
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US05232924A1

  公开（公告）日：1993-08-03

  A heterocyclic compound represented by formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl group, an aryl group which may be substituted with one or more substituents selected from the group consisting of a halogen atom, an alkoxy group, an alkyl group and a trihalogenomethyl group; .lambda. represents 0 or 1; ring A represents a 6 membered heterocyclic ring containing the nitrogen atom shared with the triazine ring and which may contain one or more double bonds; Y represents a substituted or unsubstituted alkylene group having 1 to 15 carbon atoms; and Q represents a group represented by formula (II): ##STR2## wherein R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are represented by substituents disclosed herein; or salt thereof, and intermediates therefor are described. The compound of formula (I) or salt thereof exhibit selective serotonin 2-receptor antagonistic activity and are useful for the prevention or treatment of circulatory diseases, e.g., ischemic heart diseases, cerebral vessel disturbances, and peripheral circulation disturbances.

  一种由式(I)表示的杂环化合物：##STR1##其中R1表示氢原子、烷基组、可能被一个或多个选自卤素原子、烷氧基组、烷基组和三卤甲基组的取代基取代的芳基组；λ表示0或1；环A表示含有与三嗪环共用氮原子的6元杂环环，该环可能含有一个或多个双键；Y表示具有1至15个碳原子的取代或未取代的亚烷基组；Q表示由式(II)表示的组：##STR2##其中R2、R3、R4和R5由本文披露的取代基表示；或其盐，以及其中间体。式(I)的化合物或其盐表现出对血清素2受体的选择性拮抗活性，并可用于预防或治疗循环系统疾病，例如缺血性心脏病、脑血管障碍和外周循环障碍。
• Syntheses of 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives
  作者：Yoshifumi Watanabe、Hiroyuki Usui、Shozo Kobayashi、Hirotaka Yoshiwara、Toshiro Shibano、Tsuyoshi Tanaka、Yoshiyuki Morishima、Megumi Yasuoka、Munefumi Kanao

  DOI：10.1021/jm00079a026

  日期：1992.1

  2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives with a 4-[bis(4-fluoro-phenyl)methylene]piperidine or 4-(4-fluorobenzoyl)piperidine group has been prepared and tested for 5-HT2 and alpha 1 receptor antagonist activity. Among the compounds prepared, 2-[2-[4-[bis(4-fluorophenyl)methylene]-piperidin-1-yl]ethyl]- 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one (7b) had the most

  一系列带有4- [双（4-氟-苯基）亚甲基的双环1,2,4-三唑-3（2H）-one和1,3,5-三嗪-2,4（3H）-二酮衍生物已制备]哌啶或4-（4-氟苯甲酰基）哌啶基团并测试了5-HT 2和α1受体拮抗剂的活性。在制备的化合物中，2- [2- [2- [4- [双（4-氟苯基）亚甲基]-哌啶-1-基]乙基] -5,6,7,8-四氢-1,2,4-三唑[ 4,3-a] pyridin-3（2H）-one（7b）具有最有效的5-HT2拮抗剂活性，高于利坦色林（2），而7b在体内未显示出α1拮抗剂活性。当测试阻断5-羟色氨酸诱导的头部抽搐的能力时，中央5-HT 2受体拮抗作用约为2的1/30。化合物21b，3- [2- [4-（4-氟苯甲酰基）哌啶-1-基]乙基] -6,7,8,9-四氢-2H-吡啶基[1,2-a] -1,3， 5-三嗪-2，4（3H）-二酮也显示出有效的5-HT2拮抗剂活性
• Syntheses of monocyclic and bicyclic 2,4(1H,3H)-pyrimidinediones and their serotonin 2 antagonist activities.
  作者：Yoshifumi WATANABE、Hiroyuki USUI、Toshiro SHIBANO、Tsuyoshi TANAKA、Munefumi KANAO

  DOI：10.1248/cpb.38.2726

  日期：——

  New serotonine 2(5-HT2) antagonists with a monocyclic or bicyclic 2, 4(1H, 3H)-pyrimidinedione have been prepared and their activities evaluated. In a series of monocyclic compounds, 1-substituted 5-phenyl-2, 4(1H, 3H)-pyrimidinedione 14 showed potent in vitro activity, and the corresponding 3-substituted 5-phenyl and 6-phenyl derivatives 3, 8 and 20a also showed moderate activity. In the bicyclic compounds, 3-substituted 5, 6, 7, 8-tetrahydro-2, 4(1H, 3H)-quinazolinedione 33 exhibited the most potent activity among the compounds prepared in this paper. The in vivo antagonist activity of 33 was comparable of that of ketanserin, a typical peripheral 5-HT2 antagonist.

  新型血清素2(5-HT2)拮抗剂已通过单环或双环2, 4(1H, 3H)-嘧啶二酮的合成制备，并评估了其活性。在一系列单环化合物中，1-取代的5-苯基-2, 4(1H, 3H)-嘧啶二酮14显示出强的体外活性，而相应的3-取代的5-苯基和6-苯基衍生物3、8和20a也表现出中等活性。在双环化合物中，3-取代的5, 6, 7, 8-四氢-2, 4(1H, 3H)-喹唑啉二酮33在本文中制备的化合物中表现出最强的活性。化合物33的体内拮抗活性与酮哌齐（典型的周围5-HT2拮抗剂）相当。
• Substituted cyclic amine compound, production process thereof and
  申请人：Toa Eiyo, Ltd.

  公开号：US05728835A1

  公开（公告）日：1998-03-17

  A substituted cyclic amine compound represented by the following general formula (1) ##STR1## wherein each of R.sup.1 to R.sup.5 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or the like, A represents a carbonyl group or a sulfonyl group, B represents a methine moiety or a nitrogen atom, D represents a methine moiety, a nitrogen atom or .dbd.N(.fwdarw.O)-- and n is an integer of 2 to 3; and synthetic methods thereof. The inventive compound is useful in preventing and treating circulatory organ-related diseases such as hypertension, ischemic heart disease, cerebrovascular disease, peripheral circulatory disease and the like.

  一种代表如下一般式（1）的替代环胺化合物 ##STR1## 其中R.sup.1到R.sup.5中的每一个代表氢原子、卤素原子、低烷基、低烷氧基或类似物，A代表羰基或磺酰基，B代表亚甲基团或氮原子，D代表亚甲基团、氮原子或.dbd.N(.fwdarw.O)--，n为2至3的整数；以及其合成方法。这种创新化合物在预防和治疗循环系统相关疾病，如高血压、缺血性心脏病、脑血管疾病、周围循环疾病等方面具有用处。
• 1,4-Dihydropyiridine derivative, a process for preparing the same, a pharmaceutical composition as well as the use thereof
  申请人：Eisai Co., Ltd.

  公开号：EP0197488A2

  公开（公告）日：1986-10-15

  A novel 1,4-dihydropyridine derivative is disclosed having the formula: This derivative and pharmacologically acceptable salts thereof are effective for the treatment and prevention of cardiopathy and antihypertensive and coronary vasodilating action. There is also described a process for the preparation of the claimed 1,4-dihydropyridine derivative, a pharmacological composition containing the same and the use thereof.

  公开了一种新型 1,4-二氢吡啶衍生物，其化学式为： 该衍生物及其药理学上可接受的盐类可有效治疗和预防心血管病，并具有降压和扩张冠状动脉血管的作用。 还描述了一种制备所要求的 1,4-二氢吡啶衍生物的工艺、含有该衍生物的药理组合物及其用途。